Immune circuitry in the peripheral nervous system

Current Opinion in Neurology

Volumn 19, Issue 5, 2006, Pages 437-445

  Kieseier, Bernd C ^a   Hartung, Hans Peter ^a   Wiendl, Heinz ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

B cells; Experimental autoimmune neuritis; Guillain Barr syndrome; Macrophages; Schwann cells; T lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GANGLIOSIDE GM3; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; ELECTRON MICROSCOPY; GLIA CELL; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NERVE FIBER DEGENERATION; NEUROIMMUNOLOGY; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; REGULATORY T LYMPHOCYTE; REVIEW; SCHWANN CELL; SPINAL ROOT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; MODELS, IMMUNOLOGICAL; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; SCHWANN CELLS; T-LYMPHOCYTES;

EID: 33748706141     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000245365.51823.72     Document Type: Review

References (103)

1. Gold R, Archelos JJ, Hartung HP. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 1999; 9:343-360.
2. Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30:131-156.
3. Wekerle H, Schwab M, Linington C, Meyermann R. Antigen presentation in the peripheral nervous system: Schwann cells present endogenous myelin autoantigens to lymphocytes. Eur J Immunol 1986; 16:1551-1557.
4. Mäurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002; 15:617-622.
5. Griffin JW, George R, Ho T. Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 1993; 52:553-560.
6. Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001; 64:109-127.
7. Gold R, Kieseier BC, Hartung HP. Immunological properties of the peripheral nervous system. In: Antel J, Birnbaum G, Hartung H-P, Vincent A, editors. Clinical neuroimmunology. Oxford: Oxford University Press; 2005. pp. 77-86.
8. Kaufmann SH, Schaible UE. Antigen presentation and recognition in bacterial infections. Curr Opin Immunol 2005; 17:79-87.
9. De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 2005; 5:485-496. This elegant review provides an overview on the immunologically relevant issue of the mechanisms involved in lipid presentation, the priming and clonal expansion of lipid-specific T cells, and their differentiation into memory cells.
10. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002; 125:2591-2625.
11. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 2001; 1:29-37.
12. Willison HJ. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst 2005; 10:94-112. This excellent review summarizes the scientific evidence accumulated on GBS.
13. Dalakas MC. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol 1999; 12:403-409.
14. Hartung H-P, Hughes RAC, Taylor WA. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990; 40:215-218.
15. Hartung H-P, Reiners K, Schmidt B, et al. Serum interleukin-2 concentrations in the Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30:48-53.
16. Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005; 76:1431-1439.
17. Caporale CM, Papola F, Fioroni MA, et al. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 2006 (epub ahead of print).
18. Csurhes PA, Sullivan AA, Green K, et al. Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barre syndrome. J Clin Neurosci 2005; 12:409-415.
19. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352:1343-1356. Excellent review on chronic inflammatory demyelinating polyradiculoneuropathies and its various subforms.
20. Bosboom WM, Van den Berg LH, Mollee I, et al. Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology 2001; 56:74-81.
21. Illes Z, Kondo T, Newcombe J, et al. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164:4375-4381.
22. Schmidt B, Toyka KV, Kiefer R, et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19:474-487.
23. Winer J, Hughes S, Cooper J, Ben-Smith A. Savage C. Gammadelta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002; 249:616-621.
24. Illes Z, Shimamura M, Newcombe J, et al. Accumulation of Valpha72-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 2004; 16:223-230.
25. Previtali SC, Feltri ML, Archelos JJ, et al. Role of integrins in the peripheral nervous system. Prog Neurobiol 2001; 64:35-49.
26. Previtali SC, Archelos JJ, Hartung HP. Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol 1998; 44:611-621.
27. Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002; 125:823-834.
28. Kastenbauer S, Koedel U, Wick M, et al. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003; 137:210-217.
29. Stein JV, Nombela-Arrieta C. Chemokine control of lymphocyte trafficking: a general overview. Immunology 2005; 116:1-12. Detailed overview on the complex issue of chemotactic cytokines and how the composition of these cytokines together with their specific receptors can define the composition of inflammatory infiltrates.
30. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121:159-166.
31. Leppert D, Hughes P, Huber S, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999; 53:62-70.
32. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23:975-1028.
33. Krogsgaard M, Davis MM. How T cells 'see' antigen. Nat Immunol 2005; 6:239-245. This detailed review summarizes recent work on αβ T-cell receptor recognition and discusses the implication for T-cell activation.
34. Magira EE, Papaioakim M, Nachamkin I, et al. Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 2003; 170:3074-3080.
35. Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology 2005; 65:1376-1381.
36. Wokke JH, van den Berg LH. A way out of the maze: Campylobacter jejuni gene polymorphisms define Guillain-Barre syndrome. Neurology 2005; 65:1350-1351.
37. Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999; 163:47-52.
38. Kleinschnitz C, Hofstetter HH, Meuth SG, et al. T cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression. Exp Neurol 2006 (epub ahead of print). In this elegantly conducted study the authors describe the expression pattern of the recently described novel T-cell cytokine interleukin-17A in a chronic-constriction injury model. The present data underline how T cells and T-cell-derived cytokines contribute to the inflammatory response after peripheral nerve injury.
39. Kurz M, Pischel H, Hartung HP, Kieseier BC. Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. J Peripher Nerv Syst 2005; 10:311-318.
40. Yamamoto M, Ito Y, Mitsuma N, et al. Parallel expression of neurotrophic factors and their receptors in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2002; 25:601-604.
41. Gold R, Hartung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997; 20:399-404.
42. Berghoff M, Samsam M, Muller M, et al. Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 2005; 28:118-127. In this study the authors describe the impact of immune cells on axonal integrity in a mouse model for human hereditary demyelinating neuropathies. The present data suggest that T lymphocytes exhibit a protective effect on axon survival and early-onset dysmyelination, although the precise mechanisms remain elusive.
43. Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune diseases. Curr Opin Immunol 2005; 17:577-582. Detailed overview of the concept of molecular mimicry in the context of the immunopathogenesis of Guillain-Barré syndrome.
44. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganliosides. Ann Neurol 2001; 49:712-720.
45. Hartung H-P, Willison H, Kieseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barré Syndrome. Curr Opin Neurol 2002; 15:571-577.
46. Vriesendorp FJ, Flynn RE, Pappolla MA, Koski CL. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J Neuroimmunol 1995; 58:157-165.
47. Vriesendorp FJ, Flynn RE, Pappolla MA, Koski CL. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis. Int J Neurosci 1997; 92: 287-298.
48. Santafe MM, Sabate MM, Garcia N, et al. Changes in the neuromuscular synapse induced by an antibody against gangliosides. Ann Neurol 2005; 57:396-407.
49. Halstead SK, Morrison I, O'Hanlon GM, et al. Antidisialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia 2005; 52:177-189.
50. Moran AP, Annuk H, Prendergast MM. Antibodies induced by ganglioside-mimicking Campylobacter jejuni lipooligosaccharides recognise epitopes at the nodes of Ranvier. J Neuroimmunol 2005; 165:179-185.
51. Kanda T, Yamawaki M, Mizusawa H. Sera from Guillain-Barre patients enhance leakage in blood-nerve barrier model. Neurology 2003; 60:301-306.
52. Jacobs BC, O'Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126:2220-2234.
53. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998; 10:281-290.
54. Dilley A, Gregson NA, Hadden RD, Smith KJ. Effects on axonal conduction of antiganglioside sera and sera from patients with Guillain-Barre syndrome. J Neuroimmunol 2003; 139:133-140.
55. Krampfl K, Mohammadi B, Buchwald B, et al. IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels. Muscle Nerve 2003; 27:435-441.
56. Mueller M, Wacker K, Ringelstein EB, et al. Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol 2001; 159:2187-2197.
57. Hu W, Mathey E, Hartung HP, Kieseier BC. Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 2003; 61:1774-1779.
58. Kiefer R, Kieseier BC, Hartung HP. Immune-mediated neuropathies. Adv Neurol 2002; 88:111-131.
59. Hu W, Dehmel T, Pirhonen J, et al. Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Arch Neurol 2006; 63:858-864.
60. Van Rhijn I, Van den Berg LH, Bosboom WM, et al. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000; 123:2020-2029.
61. Kiefer R, Dangond F, Mueller M, et al. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry 2000; 69:362-368.
62. Muller M, Stenner M, Wacker K, et al. Contribution of resident endoneurial macrophages to the local cellular response in experimental autoimmune neuritis. J Neuropathol Exp Neurol 2006; 65:499-507. In this very elegant study the authors provide strong evidence for the critical role of tissue-resident endoneurial macrophages in immune-mediated inflammation of the PNS.
63. Mueller M, Leonhard C, Wacker K, et al. Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages. Lab Invest 2003; 83:175-185.
64. Shubayev VI, Angert M, Dolkas J, et al. TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol Cell Neurosci 2006; 31:407-415.
65. Sommer C, Koch S, Lammens M, et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005; 27:1924-1929.
66. Lisak RP, Skundric D, Bealmear B, Ragheb S. The role of cytokines in Schwann cell damage, protection, and repair. J Infect Dis 1997; 176 (suppl 2):S173-S179.
67. Bergsteinsdottir K, Kingston A, Mirsky R, Jessen KR. Rat Schwann cells produce interleukin-1. J Neuroimmunol 1991; 34:15-23.
68. Bourde O, Kiefer R, Toyka KV, Hartung HP. Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction. J Neuroimmunol 1996; 69:135-140.
69. Gadient RA, Otten U. Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia. Brain Res 1996; 724:41-46.
70. Murwani R, Hodgkinson S, Armati P. Tumor necrosis factor alpha and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon gamma stimulation. J Neuroimmunol 1996; 71:65-71.
71. Stoll G, Jung S, Jander S, et al. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993; 45:175-182.
72. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and noninjured nerves. Neuroscience 1996; 73:625-629.
73. Scherer SS, Kamholz J, Jakowlew SB. Axons modulate the expression of transforming growth factor-betas in Schwann cells. Glia 1993; 8:265-276.
74. Stewart HJ, Rougon G, Dong Z, et al. TGF-betas upregulate NCAM and L1 expression in cultured Schwann cells, suppress cyclic AMP-induced expression of O4 and galactocerebroside, and are widely expressed in cells of the Schwann cell lineage in vivo. Glia 1995; 15:419-436.
75. Kiefer R, Funa K, Schweitzer T, et al. Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol 1996; 148:211-223.
76. Skundric DS, Lisak RP, Rouhi M, et al. Schwann cell-specific regulation of IL-1 and IL-1Ra during EAN: possible relevance for immune regulation at paranodal regions. J Neuroimmunol 2001; 116:74-82.
77. Skundric DS, Bealmear B, Lisak RP. Induced upregulation of IL-1, IL-1RA and IL-1R type I gene expression by Schwann cells. J Neuroimmunol 1997; 74:9-18.
78. Bonetti B, Valdo P, Stegagno C, et al. Tumor necrosis factor alpha and human Schwann cells: signalling and phenotype modulation without cell death. J Neuropathol Exp Neurol 2000; 59:74-84.
79. Oliveira RB, Sampaio EP, Aarestrup F, et al. Cytokines and Mycobacterium leprae induce apoptosis in human Schwann cells. J Neuropathol Exp Neurol 2005; 64:882-890.
80. Constable AL, Armati PJ, Hartung HP. DMSO induction of the leukotriene LTC4 by Lewis rat Schwann cells. J Neurol Sci 1999; 162:120-126.
81. Constable AL, Armati PJ, Toyka KV, Hartung HP. Production of prostanoids by Lewis rat Schwann cells in vitro. Brain Res 1994; 635:75-80.
82. Ahn M, Lee Y, Moon C, et al. Upregulation of osteopontin in Schwann cells of the sciatic nerves of Lewis rats with experimental autoimmune neuritis. Neurosci Lett 2004; 372:137-141.
83. Hase A, Saito F, Yamada H, et al. Characterization of glial cell line-derived neurotrophic factor family receptor alpha-1 in peripheral nerve Schwann cells. J Neurochem 2005; 95:537-543. This study provides strong evidence for the expression of a neurotrophic-factor-associated receptor, GFRα-1, and adds data on its expression and function in the PNS.
84. Iwase T, Jung CG, Bae H, et al. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J Neurochem 2005; 94:1488-1499.
85. Pereira RM, Calegari-Silva TC, Hernandez MO, et al. Mycobacterium leprae induces NF-kappaB-dependent transcription repression in human Schwann cells. Biochem Biophys Res Commun 2005; 335:20-26.
86. Laura M, Mazzeo A, Aguennouz M, et al. Immunolocalization and activation of nuclear factor-kappaB in the sciatic nerves of rats with experimental autoimmune neuritis. J Neuroimmunol 2006; 174:32-38.
87. Andorfer B, Kieseier BC, Mathey E, et al. Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. J Neuroimmunol 2001; 116:226-232.
88. Wohlleben G, Hartung HP, Gold R. Humoral and cellular immune functions of cytokine-treated Schwann cells. Adv Exp Med Biol 1999; 468:151-156.
89. Keswani SC, Buldanlioglu U, Fischer A, et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 2004; 56:815-826.
90. Campana WM, Li X, Shubayev VI, et al. Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 2006; 23:617-626.
91. Armati PJ, Pollard JD, Gatenby P. Rat and human Schwann cells in vitro can synthesize and express MHC molecules. Muscle Nerve 1990; 13:106-116.
92. Bergsteinsdottir K, Kingston A, Jessen KR. Rat Schwann cells can be induced to express major histocompatibility complex class II molecules in vivo. J Neurocytol 1992; 21:382-390.
93. Gold R, Toyka KV, Hartung HP. Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol 1995; 165:65-70.
94. Samuel NM, Mirsky R, Grange JM, Jessen KR. Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with Mycobacterium leprae. Clin Exp Immunol 1987; 68:500-509.
95. Kingston AE, Bergsteinsdottir K, Jessen KR, et al. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction. Eur J Immunol 1989; 19:177-183.
96. Tsai CP, Pollard JD, Armati PJ. Interferon-gamma inhibition suppresses experimental allergic neuritis: modulation of major histocompatibility complex expression of Schwann cells in vitro. J Neuroimmunol 1991; 31:133-145.
97. Pollard JD, Baverstock J, McLeod JG. Class II antigen expression and inflammatory cells in the Guillain-Barre syndrome. Ann Neurol 1987; 21:337-341.
98. Pollard JD, McCombe PA, Baverstock J, et al. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1986; 13:123-134.
99. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997; 15:821-850.
100. Bigbee JW, Yoshino JE, DeVries GH. Morphological and proliferative responses of cultured Schwann cells following rapid phagocytosis of a myelin-enriched fraction. J Neurocytol 1987; 16:487-496.
101. Lilje O. The processing and presentation of endogenous and exogenous antigen by Schwann cells in vitro. Cell Mol Life Sci 2002; 59:2191-2198.
102. Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000; 123:1660-1666.
103. Pollard JD. Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 2002; 15:279-283.